Fibrin Sealants: Challenges and Solutions
Source abstract
Abstract
Intraoperative bleeding and postoperative bleeding are major surgical complications. Tissue sealants, hemostats, and adhesives provide the armamentarium for establishing hemostatic balance, including the tissue sealant fibrin. Fibrin sealants combine advantages including instantaneous effect, biocompatibility, and biodegradability. However, several challenges remain. This review summarizes current fibrin product generations and highlights new trends and potential strategies for future improvement.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Hemostasis and retained surgical items · Surgical Sutures and Adhesives · Blood transfusion and management
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Institute of Pharmacy and Food Chemistry, Julius-Maximilians-University Würzburg, Am Hubland, 97074 Würzburg, Germany
Helmholtz Institute for RNA-based Infection Research, Josef-Schneider-Straße 2, 97080 Würzburg, Germany
Funding
Deutsche Forschungsgemeinschaft
References (100+)
Show source-provided references
1. 10.1016/S0140-6736(15)60160-X10.1016/S0140-6736(15)60160-X ↗
2. 10.34297/AJBSR.2019.02.00061010.34297/AJBSR.2019.02.000610 ↗
3. 10.1186/1472-6963-11-13510.1186/1472-6963-11-135 ↗
4. 10.1016/j.surg.2007.06.02510.1016/j.surg.2007.06.025 ↗
5. 10.1159/00010366010.1159/000103660 ↗
6. 10.1016/j.gassur.2006.02.00210.1016/j.gassur.2006.02.002 ↗
7. 10.1007/88-470-0407-1_6210.1007/88-470-0407-1_62 ↗
8. 10.1002/bjs.180082033210.1002/bjs.1800820332 ↗
9. 10.1186/s13019-019-0881-310.1186/s13019-019-0881-3 ↗
10. 10.1016/j.jtcvs.2009.02.02110.1016/j.jtcvs.2009.02.021 ↗
11. 10.1160/TH16-09-072110.1160/TH16-09-0721 ↗
12. 10.1038/s41578-019-0171-710.1038/s41578-019-0171-7 ↗
13. 10.1186/s13063-019-3492-310.1186/s13063-019-3492-3 ↗
14. 10.1128/JCM.02442-1210.1128/JCM.02442-12 ↗
15. 10.1615/CritRevBiomedEng.201401167610.1615/CritRevBiomedEng.2014011676 ↗
16. 10.1021/acs.biomac.7b0096910.1021/acs.biomac.7b00969 ↗
17. 10.1177/107602961036358910.1177/1076029610363589 ↗
18. Global Medical Adhesives and Sealants Industry. Reportlinker. https://www.reportlinker.com/p05478477/Global-Medical-Adhesives-and-Sealants-Industry.html?utm_source=GNW (accessed 2021-11-08).
19. 10.1039/C3TB21739F10.1039/C3TB21739F ↗
20. 10.1002/adma.20170085910.1002/adma.201700859 ↗
21. Ethicon OMNEX Surgical Sealant - FDA Premarket Approval (PMA) P060029. U.S. Food and Drug Administration. https://fda.report/PMA/P060029 (accessed 2021-11-08).
22. Premarket Approval (PMA) Cohera medical TISSUGLU. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scrIpts/cdrh/cfdocs/cfpma/pma.cfm?id=P130023 (accessed 2021-11-08).
23. Premarket Approval (PMA) DuraSeal Dural EXACT Sealant System. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P040034S032 (accessed 2021-11-08).
24. Premarket Approval (PMA) FOCAL SEAL-L SYNTHETIC ABSORBABLE SEALANT. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P990028 (accessed 2021-11-08).
25. Premarket Approval (PMA) DERMABOND (A FORMULATION OF 2-OCTYLCYANOACRYLATE). U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=p960052 (accessed 2021-11-08).
26. Premarket Approval (PMA) Progel Pleural Air Leak Sealant (Progel PALS). U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P010047S064 (accessed 2021-11-08).
27. Premarket Approval (PMA) BioGlue Surgical Adhesive. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P010003S037 (accessed 2021-11-08).
28. Mintz P. D. · Ann. Clin. Lab. Sci. · 2001 · 31 · 108
29. 10.1111/j.1537-2995.2008.01703.x10.1111/j.1537-2995.2008.01703.x ↗
30. 10.1152/physrev.00016.201110.1152/physrev.00016.2011 ↗
31. 10.1309/50UQ-GUPF-W6XW-1X7B10.1309/50UQ-GUPF-W6XW-1X7B ↗
32. 10.21037/jlpm.2018.07.0710.21037/jlpm.2018.07.07 ↗
33. 10.1160/TH12-10-077210.1160/TH12-10-0772 ↗
34. 10.1023/B:THRO.0000014588.95061.2810.1023/B:THRO.0000014588.95061.28 ↗
35. 10.1007/978-94-007-7741-5_22-110.1007/978-94-007-7741-5_22-1 ↗
36. 10.1161/01.ATV.0000193624.28251.8310.1161/01.ATV.0000193624.28251.83 ↗
37. 10.1055/s-2006-93955210.1055/s-2006-939552 ↗
38. 10.1046/j.1538-7836.2003.00298.x10.1046/j.1538-7836.2003.00298.x ↗
39. 10.1111/j.1440-1797.2009.01128.x10.1111/j.1440-1797.2009.01128.x ↗
40. 10.1177/019262331038947410.1177/0192623310389474 ↗
41. 10.1155/2014/78185710.1155/2014/781857 ↗
42. 10.1016/S0006-3495(01)76085-710.1016/S0006-3495(01)76085-7 ↗
43. 10.1161/01.ATV.0000130465.23430.7410.1161/01.ATV.0000130465.23430.74 ↗
44. 10.1093/labmed/lmx05010.1093/labmed/lmx050 ↗
45. 10.1182/blood.V100.3.74310.1182/blood.V100.3.743 ↗
46. 10.1016/j.blre.2014.09.00310.1016/j.blre.2014.09.003 ↗
47. 10.1046/j.1538-7836.2003.00334.x10.1046/j.1538-7836.2003.00334.x ↗
48. 10.1371/journal.pone.000840310.1371/journal.pone.0008403 ↗
49. 10.1016/S0021-9258(18)50131-910.1016/S0021-9258(18)50131-9 ↗
50. 10.1042/bj094073510.1042/bj0940735 ↗
51. 10.1006/bcmd.2000.033010.1006/bcmd.2000.0330 ↗
52. 10.1007/BF0016616410.1007/BF00166164 ↗
53. 10.1002/prot.2278310.1002/prot.22783 ↗
54. 10.1002/0471250953.bi0301s4210.1002/0471250953.bi0301s42 ↗
55. 10.1021/bi00451a03910.1021/bi00451a039 ↗
56. 10.1021/bi00369a02610.1021/bi00369a026 ↗
57. 10.1021/bi00322a01410.1021/bi00322a014 ↗
58. 10.1021/bi020299t10.1021/bi020299t ↗
59. 10.1111/j.1538-7836.2005.01365.x10.1111/j.1538-7836.2005.01365.x ↗
60. 10.1007/BF0316528410.1007/BF03165284 ↗
61. 10.1021/bi802205g10.1021/bi802205g ↗
62. 10.1172/JCI11184910.1172/JCI111849 ↗
63. 10.1073/pnas.030344010110.1073/pnas.0303440101 ↗
64. 10.1182/blood-2010-08-30030110.1182/blood-2010-08-300301 ↗
65. 10.1002/mabi.20190028310.1002/mabi.201900283 ↗
66. 10.1155/2017/274834010.1155/2017/2748340 ↗
67. 10.1007/s00268-009-0252-710.1007/s00268-009-0252-7 ↗
68. 10.1155/2014/20394310.1155/2014/203943 ↗
69. 10.1046/j.1537-2995.1995.35996029166.x10.1046/j.1537-2995.1995.35996029166.x ↗
70. 10.1097/MBC.0b013e32833fcbfb10.1097/MBC.0b013e32833fcbfb ↗
71. Australian Public Assessment Report for Fibrin Sealant. Therapeutic Goods Administration, October 2010. https://www.tga.gov.au/sites/default/files/auspar-artiss.pdf (accessed 2022-01-24).
72. 10.1055/s-0029-120139510.1055/s-0029-1201395 ↗
73. 10.1097/00000658-191807000-0001110.1097/00000658-191807000-00011 ↗
74. 10.1001/jama.1944.0285014002200610.1001/jama.1944.02850140022006 ↗
75. 10.5555/uri:pii:S003960604490052810.5555/uri:pii:S0039606044900528 ↗
76. Hile J. · FDA Drug Bull. · 1978 · 8 · 15
77. Malarkey, M. A.; Epstein, J. S. Approval Letter - RAPLIXA, 2015. U.S. Food and Drug Administration, April 30, 2015. http://wayback.archive-it.org/7993/20170723024734/https://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/UCM445351.pdf (accessed 2021-11-08).
78. 10.1016/S0887-7963(03)00041-510.1016/S0887-7963(03)00041-5 ↗
79. Baxter Healthcare Corp. Package Insert - TISSEEL. U.S. Food and Drug Administration, n.d. https://www.fda.gov/media/71674/download (accessed 2021-11-08).
80. Baxter Deutschland GmbH. DUPLOSPRAY MIS-Applikator. Paul-Ehrlich-Institute, 2018. https://www.pei.de/SharedDocs/schulungsmaterial/Tisseel-Schulungsmaterial-Aerzte_Version-1_Kurzanleitung.pdf?__blob=publicationFile&v=2 (accessed 2021-11-08).
81. DUPLOSPRAY Quick Reference Guide (laparoscopic procedures). Baxter Healthcare Ltd. https://www.hpra.ie/docs/default-source/3rd-party-documents/educational-materials/tisseel_hcp_duplospray-qrg_v1-07-15.pdf (accessed 2022-05-22).
82. 10.1016/S0003-4975(98)00470-610.1016/S0003-4975(98)00470-6 ↗
83. Garbasch, A.; Hvid, N.; Cianciolo, D. Applicator and electro-mechanical applicator drive system. US 6234356 B1, May 22, 2001.
84. 10.1016/j.ejcts.2004.08.00910.1016/j.ejcts.2004.08.009 ↗
85. Vivostat PRF® - A New Approach to Tissue Regeneration. Sacomed A/S, n.d. https://sacomed.com/wp-content/uploads/2019/09/Vivostat-PRF.pdf (accessed 2021-11-08).
86. Controlling Bleeds during Surgery. Team Consulting Ltd. https://www.team-consulting.com/work/controlling-bleeds-during-surgery/ (accessed 2021-11-08).
87. Greenhalgh, P.; Grimbergen, J. M.; Harvey, O. Powder Delivery Device. WO 2010070333 A2, June 24, 2010.
88. Greenhalgh, P.; Schutte, E. Powder delivery device. US 10010705 B2, March 7, 2018.
89. The Medicines Company, Inc. The Medicines Company: Raplixa Approval is Likely, Manufacturing Risk Is Low. Seeking Alpha. https://seekingalpha.com/article/2865416-the-medicines-company-raplixa-approval-is-likely-manufacturing-risk-is-low (accessed 2021-11-08).
90. 10.1007/s40261-015-0307-510.1007/s40261-015-0307-5 ↗
91. Johnson & Johnson Medical N.V. Coated VICRYL (polyglactin 910) Suture. Ethicon. https://www.jnjmedicaldevices.com/en-EMEA/product/coated-vicryl-polyglactin-910-suture (accessed 2021-11-08).
92. 10.3109/08941939.2014.94144410.3109/08941939.2014.941444 ↗
93. Ethicon, Inc. Package Insert - EVARREST. U.S. Food and Drug Administration, 2016. https://www.fda.gov/media/85265/download (accessed 2021-11-08).
94. 10.1016/S0967-2109(03)00065-610.1016/S0967-2109(03)00065-6 ↗
95. 10.1016/j.ejvs.2020.05.01610.1016/j.ejvs.2020.05.016 ↗
96. 10.1002/jhbp.38910.1002/jhbp.389 ↗
97. 10.1007/s00268-020-05621-z10.1007/s00268-020-05621-z ↗
98. 10.1371/journal.pone.015153310.1371/journal.pone.0151533 ↗
99. Lindsey, K. Clinical Review - Tisseel STN: 103980/5601, U.S. Food and Drug Administration, n.d. https://www.fda.gov/media/83108/download (accessed 2021-11-08).
100. Federal Institute for Drugs and Medical Devices Germany. Beriplast P Combi-Set 0,5 mL. Paul-Ehrlich-Institute.https://www.pei.de/DE/arzneimittel/blutprodukte/fibrinkleber/fibrinkleber-node.html (accessed 2021-11-08).